Travere Therapeutics, Inc. - Common Stock (TVTX)

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT.

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that company management will present in the following upcoming investor conferences in December:

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.00 per share, including 1,171,875 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $143.8 million, before deducting the underwriting discounts and commissions and offering expenses.

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that company management will present in the following upcoming investor conferences in November:

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQTVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET.

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQTVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TVTX.

Company to host conference call today at 4:30 p.m. ET

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years

Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that company management will present in the following upcoming investor conferences in August:

CS Diagnostics Group (OTC: FZRO) signed a landmark agreement to sell and transfer tangible and intangible assets, including patents, for the CS Protect-Hydrogel to CS Diagnostics Corp. The hydrogel-based tissue spacer, designed for radiation therapy, increases the distance between healthy tissue and cancer cells, protecting healthy tissues from high radiation doses.

Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQTVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).